Literature DB >> 15908304

Necrobiotic xanthogranuloma associated with lymphoplasmacytic lymphoma. Palliative treatment with carbon dioxide laser.

V Vieira1, J Del Pozo, W Martínez, J A Veiga-Barreiro, E Fonseca.   

Abstract

Necrobiotic xanthogranuloma (NXG) with paraproteinemia is a rare non-x histiocytosis with conspicuous lesions mainly located on the periorbital skin. A 68-year-old woman, with a previous history of lymphoplasmacytic lymphoma associated with IgG monoclonal gammopathy over a period of almost 4 years, presented typical lesions of NXG on the periorbital regions and left buttock. Treatment with dioxide carbon laser resulted in great improvement of cutaneous lesions, and no evidence of relapse after a 12-month follow-up. The association of NXG with lymphoplasmacytic lymphoma has not been previously described to our knowledge. The treatment of these lesions represents a true challenge for the clinician and palliative treatment of cutaneous lesions of NXG with CO(2) laser may constitute an alternative treatment in selected cases.

Entities:  

Mesh:

Year:  2005        PMID: 15908304

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  3 in total

1.  Necrobiotic xanthogranuloma.

Authors:  Yvonne Efebera
Journal:  Clin Adv Hematol Oncol       Date:  2011-09

Review 2.  Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature.

Authors:  Yvonne Efebera; Elizabeth Blanchard; Charles Allam; Andrew Han; Saem Lee; Nikhil Munshi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-04-20

3.  A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria.

Authors:  Caroline A Nelson; Connie S Zhong; David A Hashemi; Hovik J Ashchyan; Zoe Brown-Joel; Megan H Noe; Sotonye Imadojemu; Robert G Micheletti; Ruth Ann Vleugels; Karolyn A Wanat; Misha Rosenbach; Arash Mostaghimi
Journal:  JAMA Dermatol       Date:  2020-03-01       Impact factor: 10.282

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.